Patent ID: 9200049
Filing Date: 2015-12-01
Classification: A61K,A61P,C07K,C12P

Abstract:
1. A Fibroblast Growth Factor-21 (FGF-21) conjugate comprising a mutant FGF-21 peptide and a modifying group, wherein the mutant FGF-21 peptide has the sequence of SEQ ID NO: 146 except for the presence of at least one potential O-linked or N-linked glycosylation site not present in SEQ ID NO: 146, wherein the mutant FGF-21 peptide contains an amino acid sequence selected from the group consisting of SEQ ID NOs: 323-325, wherein the O-linked glycosylation site is a serine or threonine residue and the N-linked glycosylation site is an asparagine, wherein the O-linked or N-linked glycosylation site is present at a site within SEQ ID NO: 323, 324, or 325, wherein said modifying group is selected from the group consisting of water-soluble polymers, therapeutic moieties, diagnostic moieties, targeting moieties, and biomolecules, wherein said modifying group is covalently attached to said peptide at a preselected glycosyl or amino acid residue of said peptide via an intact glycosyl linking group, wherein said modifying group is not a naturally occurring saccharide moiety, and wherein the FGF-21 conjugate retains a biological activity of SEQ ID NO: 146.